Literature DB >> 2309825

Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma.

B Patsner1, J W Orr, W J Mann.   

Abstract

Serum CA 125 levels were normal preoperatively in 123 of 125 (98.4%) patients with clinical and surgical stage I or II endometrial adenocarcinoma, and remained so in all patients who remained without evidence of either isolated vaginal recurrence or postoperative radiation enteritis. Recurrent disease developed in 13 patients. All of those who had pelvic (1), abdominal (4), or pulmonary (2) metastases had elevated serum CA 125 levels. None of the six patients with isolated vaginal recurrences had elevated CA 125 levels. Four patients had small bowel obstruction as a result of postoperative pelvic radiation, and all had elevated CA 125 levels during these episodes, although no evidence of recurrent disease was found during exploratory laparotomy for intestinal bypass. Serum CA 125 levels may have a role in the posttreatment surveillance of patients with early-stage endometrial carcinoma, but may be falsely elevated in the presence of severe radiation injury and at a normal level in the presence of isolated vaginal metastases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309825     DOI: 10.1016/0002-9378(90)90400-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Authors:  Roberto Angioli; Stella Capriglione; Giuseppe Scaletta; Alessia Aloisi; Andrea Miranda; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2015-11-03

2.  Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

Authors:  Donal J Brennan; Andreas Hackethal; Kristy P Mann; Irene Mutz-Dehbalaie; Heidi Fiegl; Christian Marth; Andreas Obermair
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

3.  Stratification of risk groups according to survival after recurrence in endometrial cancer patients.

Authors:  Seung-Hyuk Shim; Dae-Yeon Kim; Hyun Jung Kim; Shin-Wha Lee; Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

4.  Cancer antigen 125 is associated with disease status in uterine carcinosarcoma.

Authors:  Malcolm Strachan Ross; Chelsea Kilpatrick Chandler; Koji Matsuo; John Austin Vargo; Esther Elishaev; Nalyn Siripong; Jessica Layne Berger; Joseph Leo Kelley; Sarah Elizabeth Taylor
Journal:  Rare Tumors       Date:  2019-11-07

Review 5.  Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012.

Authors:  Bruce Patsner; Ga Won Yim
Journal:  Obstet Gynecol Sci       Date:  2013-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.